Andrew S. Levey (born September 16, 1950) is an American nephrologist who transformed chronic kidney disease (CKD) clinical practice, research, and public health by developing equations to estimate glomerular filtration rate (GFR) (renal function), and leading the global standardization of CKD definition and staging.
Levey is known for developing the most widely used equations to estimate GFR (renal function) globally. He pioneered work with the MDRD Study Equation, [1] led the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), which pooled measured kidney function CKD data from studies all over the world to develop equations to estimate kidney function from serum creatinine, cystatin C, and panels of metabolites and low-molecular-weight proteins.[2][3][4] The 2009 creatinine equation with race and the 2021 creatinine equation without race to replace the 2009 equation are shown below:
For both equations, α is -0.241 for females and -0.302 for males; min indicates minimum of Scr/k or 1, and max indicates maximum of Scr/k or 1
Levey is an authority on clinical practice guidelines in kidney disease. He chaired the U.S. National Kidney Foundation Kidney Disease Outcome Quality Initiative (KDOQI) Clinical Practice Guideline Workgroup on “Chronic Kidney Disease: Evaluation, Classification and Risk Stratification”[5]. The recommendations from this workgroup transformed the way Kidney Disease was defined and staged globally. The guideline has been cited over 10,000[6] times in subsequent research publications. He led multiple KDOQI and Kidney Disease Improving Global Outcomes (KDIGO)[7] guidelines which advanced the global recognition and care for CKD,[8][9][10][11]hypertension,[12]acute kidney injury,[7]living kidney donor evaluation,[13] and nomenclature.[14]
Levey was a founding member of the Chronic Kidney Disease Prognosis Consortium (CKDPC),[15] which includes over 80 cohorts and 10 million[16] participants and has informed multiple clinical practice guidelines and regulatory policies.
Levey led the U.S. National Kidney Foundation task force on cardiovascular disease in chronic kidney disease, which led to the recognition by the American Heart Association of CKD as a risk factor for cardiovascular disease.[17][18]
Levey co-chaired the U.S. Centers for Disease Control and Prevention expert panel to develop comprehensive public health strategies for preventing the development, progression, and complications of CKD.[19]
Levey led scientific workshops sponsored by the U.S. National Kidney Foundation in collaboration with the U.S. Food and Drug Administration and European Medicines Association for the evaluation of Renal function as surrogate endpoints for clinical trials of kidney disease progression.[20][21][22]
Levey was editor-in-chief for American Journal of Kidney Diseases, the official journal of the U.S. National Kidney Foundation, from 2007-2016.
Tufts University School of Medicine: Dean’s Award for Excellence in Teaching (1986), Dr. Gerald J. and Dorothy R. Friedman Professor of Medicine (1999), Distinguished Faculty Award (2004), Dr. Gerald J. and Dorothy R. Friedman Professor of Medicine Emeritus (2017), Zucker Family Prize for Research (2019)
^Levey, Andrew (1999). "A More Accurate Method to Estimate Glomerular Filtration Rate From Serum Creatinine: A New Prediction Equation. Modification of Diet in Renal Disease Study Group". Ann Intern Med. 130 (6): 461–70. doi:10.7326/0003-4819-130-6-199903160-00002. PMID10075613. S2CID1902375.
^Levey, Andrew (2004). "K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease". American Journal of Kidney Diseases. 5 (1): S1-290. PMID15114537.
^Levey, Andrew (1998). "Controlling the Epidemic of Cardiovascular Disease in Chronic Renal Disease: What Do We Know? What Do We Need to Learn? Where Do We Go From Here? National Kidney Foundation Task Force on Cardiovascular Disease". American Journal of Kidney Diseases. 32 (5): 853–906. doi:10.1016/s0272-6386(98)70145-3. PMID9820460.
^Levey, Andrew (2003). "Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention". Circulation. 108 (17): 2154–69. doi:10.1161/01.CIR.0000095676.90936.80. PMID14581387. S2CID2530900.
^Levey, Andrew (2009). "Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration". American Journal of Kidney Diseases. 54 (2): 205–26. doi:10.1053/j.ajkd.2009.04.029. PMID19577347.
^Levey, Andrew (2014). "GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration". American Journal of Kidney Diseases. 64 (6): 821–35. doi:10.1053/j.ajkd.2014.07.030. PMID25441437.
^English, Bella (March 28, 2010). "Harvesting hope from a giving tree". Archived from the original on April 1, 2022. Retrieved May 24, 2020.{{cite news}}: CS1 maint: bot: original URL status unknown (link)